scholarly journals Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction

2011 ◽  
Vol 13 (6) ◽  
pp. 819-827 ◽  
Author(s):  
Vittorio Magri ◽  
Emanuele Montanari ◽  
Višnja Škerk ◽  
Alemka Markotić ◽  
Emanuela Marras ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Combination Therapy ◽  
Retrospective Analysis ◽  
Chronic Bacterial Prostatitis ◽  
Bacterial Prostatitis

Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis

2007 ◽  
Vol 29 (5) ◽  
pp. 549-556 ◽  
Author(s):  
Vittorio Magri ◽  
Alberto Trinchieri ◽  
Giacomo Pozzi ◽  
Antonella Restelli ◽  
Maria Cristina Garlaschi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Chronic Bacterial Prostatitis ◽  
Bacterial Prostatitis ◽  
Infecting Organisms

99: Prulifloxacin Versus Levofloxacin in the Treatment of Chronic Bacterial Prostatitis: A Prospective, Randomized, Double-Blind Trial

2007 ◽  
Vol 177 (4S) ◽  
pp. 35-35
Author(s):  
Gianluca Giannarini ◽  
Andrea Mogorovich ◽  
Girolamo Morelli ◽  
Maurizio De Maria ◽  
Francesca Manassero ◽  
...  
Keyword(s):  
Double Blind Trial ◽  
Chronic Bacterial Prostatitis ◽  
Double Blind ◽  
Blind Trial ◽  
Bacterial Prostatitis

scholarly journals The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study

2021 ◽  
Author(s):  
Tommaso Cai ◽  
Luca Gallelli ◽  
Erika Cione ◽  
Gianpaolo Perletti ◽  
Francesco Ciarleglio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Clinical Status ◽  
Well Being ◽  
Antibiotic Use ◽  
Chronic Bacterial Prostatitis ◽  
Symptomatic Recurrence ◽  
Bacterial Prostatitis ◽  
Phase Iv

Abstract Purpose To evaluate the efficacy of Lactobacillus paracasei CNCM I-1572 (L. casei DG®) in both prevention of symptomatic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP). Methods Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG® (2 capsules/day for 3 months). Clinical and microbiological analyses were carried out before (enrollment, T0) and 6 months (T2) after the treatment. Both safety and adherence to the treatment were evaluated 3 months (T1) after the enrollment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use. Results Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5 ± 3.58; − 11.0 ± 4.32; + 0.3 ± 0.09; p < 0.001), was reported. We recorded that L. casei DG® treatment induced a statistically significant decrease in both (p < 0.001) symptomatic recurrence [1.9/3 months vs 0.5/3 months] and antibiotic use [− 7938 UDD]. No clinically relevant adverse effects were reported. Conclusions L. casei DG® prevents symptomatic recurrences and improves the quality of life in patients with CBP, reducing the antibiotic use.

scholarly journals Concentrations of Gatifloxacin in Plasma and Urine and Penetration into Prostatic and Seminal Fluid, Ejaculate, and Sperm Cells after Single Oral Administrations of 400 Milligrams to Volunteers

2001 ◽  
Vol 45 (1) ◽  
pp. 293-297 ◽  
Author(s):  
Christoph K. Naber ◽  
Michaela Steghafner ◽  
Martina Kinzig-Schippers ◽  
Christian Sauber ◽  
Fritz Sörgel ◽  
...  
Keyword(s):  
Maximum Concentration ◽  
Seminal Fluid ◽  
Plasma Concentrations ◽  
Sperm Cells ◽  
Chronic Bacterial Prostatitis ◽  
Time Curve ◽  
Chromatography Method ◽  
Simultaneous Application ◽  
Bacterial Prostatitis ◽  
Antibacterial Spectrum

ABSTRACT Gatifloxacin (GTX), a new fluoroquinolone with extended antibacterial activity, is an interesting candidate for the treatment of chronic bacterial prostatitis (CBP). Besides the antibacterial spectrum, the concentrations in the target tissues and fluids are crucial for the treatment of CBP. Thus, it was of interest to investigate its penetration into prostatic and seminal fluid. GTX concentrations in plasma, urine, ejaculate, prostatic and seminal fluid, and sperm cells were determined by a high-performance liquid chromatography method after oral intake of a single 400-mg dose in 10 male Caucasian volunteers in the fasting state. Simultaneous application of the renal contrast agent iohexol was used to estimate the maximal possible contamination of ejaculate and prostatic and seminal fluid by urine. GTX was well tolerated. The means (standard deviations) for the following parameters were as indicated: time to maximum concentration of drug in serum, 1.66 (0.91) h; maximum concentration of drug in serum, 2.90 (0.39) μg/ml; area under the concentration-time curve from 0 to 24 h, 25.65 μg · h/ml; and half life, 7.2 (0.90) h. Within 12 h about 50% of the drug was excreted unchanged into the urine. The mean renal clearance was 169 ml/min. The gatifloxacin concentrations in ejaculate, seminal fluid, and prostatic fluid were in the range of the corresponding plasma concentrations which were 1.92 (0.27) μg/ml at approximately the same time point (4 h after drug intake). The concentrations in sperm cells (0.195, 0.076, and 0.011 μg/ml) could be determined in three subjects. The good penetration into prostatic and seminal fluid, the good tolerance, and the previously reported broad antibacterial spectrum suggest that GTX may be a good alternative for the treatment of chronic bacterial prostatitis. Clinical studies should be performed to confirm this assumption.

420 The role of microscopic examination in the diagnosis of chronic bacterial prostatitis

2018 ◽  
Vol 15 (7) ◽  
pp. S272-S273
Author(s):  
K.S. Ibishev ◽  
D.V. Krakhotkin ◽  
P.A. Krainiy ◽  
Z.M. Zagirov ◽  
R.G. Magomedov
Keyword(s):  
Microscopic Examination ◽  
Chronic Bacterial Prostatitis ◽  
Bacterial Prostatitis

scholarly journals Serenoa repens extract additionally to quinolones in the treatment of chronic bacterial prostatitis. The preliminary results of a long term observational study

2013 ◽  
Vol 85 (4) ◽  
pp. 190 ◽  
Author(s):  
Konstantinos Stamatiou ◽  
Nikolaos Pierris
Keyword(s):  
Sexual Dysfunction ◽  
Chronic Prostatitis ◽  
Bacterial Eradication ◽  
Serenoa Repens ◽  
Chronic Bacterial Prostatitis ◽  
Local Pain ◽  
Clinical Criteria ◽  
Preliminary Results

Introduction: Chronic prostatitis displays a variety of symptoms (mainly local pain exhibiting variability in origin and intensity). The purpose of this article is to briefly present the preliminary results of our study examining the role of phytotherapeutic agents in the treatment of chronic prostatitis patients. Materials and methods: The study included in total fifty-six consecutive patients who visited the outpatient department. Subjects were randomized into two groups. Subjects in the first group (28 patients) received prulifloxacin 600 mg for 15 days, while subjects in the second group (28 patients) received prulifloxacin 600 mg for 15 days and Serenoa repens extract for 8 weeks. The response was tested using laboratory and clinical criteria. Results: We found statistically significant differences between the two groups regarding pain regression and no statistically significant regarding bacterial eradication. Moreover however while sexual dysfunction improvement was equally achieved in both groups, improvement of urinary symptoms was more evident in the 2nd group especially after the completion of the antibiotic treatment. Conclusions: Serenoa repens extract for 8 weeks seems to improve prostatitis related pain. Further randomized, placebo-controlled studies are needed to substantiate safer conclusions.

Sign in / Sign up

Export Citation Format

Share Document